融券方面，睿智医药8月27日融券偿还600.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量8900.00股，融券余额11.03万元，超过近一年60%分位水平，处于较高位。 资料显示，睿智医药科技股份有限公司位于广东省广州市越秀区东风中路268号交易广场28楼，成立日 期2000年1月26日，上市日期2010年12月22日，公司主营业务涉及医药研发与生产外包服务、微生态营 养、微生态医疗。主营业务收入构成为：药效药动业务56.39%，化学业务26.41%，大分子业务 16.23%，其他业务收入0.97%。 截至8月8日，睿智医药股东户数5.25万，较上期减少18.89%；人均流通股9467股，较上期增加23.28%。 2025年1月-3月，睿智医药实现营业收入2.61亿元，同比增长11.37%；归母净利润664.21万元，同比增长 126.09%。 8月27日，睿智医药跌4.18%，成交额3.88亿元。两融数据显示，当日睿智医药获融资买入额3889.76万 元，融资偿还4771.84万元，融资净买入-882.08万元。截至8月27日，睿智医药融资融券余额合计2.84亿 元。 融资方 ...

资金流向方面，6月9日，睿智医药主力资金净流入24543.61万元，近5日总体呈流出状态，5日共流出 12120.23万元。 6月9日，睿智医药今日收盘11.65元，上涨19.98%，最新市净率4.75，创600天以来新低，总市值58.01亿 元。 睿智医药科技股份有限公司的主营业务是为全球制药企业、生物技术公司以及科研院校提供药物发现、 开发以及生产服务。公司的主要产品是化学业务、药效药动业务、大分子业务。 最新一期业绩显示，2025年一季报，公司实现营业收入2.61亿元，同比11.37%；净利润664.21万元，同 比126.09%，销售毛利率27.44%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11睿智医药-29.85-25.624.7558.01亿行业平均 41.4247.583.52160.55亿行业中值44.3250.812.7559.92亿1润达医疗-298.01197.212.57109.02亿2何氏眼 科-154.96-134.851.9336.95亿3*ST生物-139.41-135.5311.4526.90亿4诚达药业-74.10-126.951.6735.68亿5普 瑞 ...

Core Viewpoint - The company, Ruizhi Pharmaceutical, is experiencing a decline in stock price and net capital outflow, despite showing positive revenue and profit growth in its latest quarterly report [1][2]. Company Summary - Ruizhi Pharmaceutical's stock closed at 10.16 yuan on June 5, down 3.05%, with a latest price-to-book ratio of 4.15 and a total market capitalization of 5.059 billion yuan [1]. - The company reported a net capital outflow of 83.8388 million yuan on June 5, with a total outflow of 156.9818 million yuan over the past five days [1]. - The main business of Ruizhi Pharmaceutical includes providing drug discovery, development, and production services to global pharmaceutical companies, biotechnology firms, and research institutions [1]. - The company's primary products consist of chemical business, pharmacodynamics and pharmacokinetics, and macromolecule business [1]. - In the first quarter of 2025, the company achieved a revenue of 261 million yuan, representing a year-on-year increase of 11.37%, and a net profit of 6.6421 million yuan, reflecting a year-on-year growth of 126.09%, with a sales gross margin of 27.44% [1]. Industry Summary - The average price-to-earnings (PE) ratio for the industry is 40.82 (TTM) and 46.97 (static), with an average price-to-book ratio of 3.46 [2]. - The median PE ratio for the industry is 45.93 (TTM) and 53.09 (static), with a median price-to-book ratio of 2.73 [2].

最新一期业绩显示，2025年一季报，公司实现营业收入2.61亿元，同比11.37%；净利润664.21万元，同 比126.09%，销售毛利率27.44%。 6月3日，睿智医药今日收盘11.62元，上涨13.15%，最新市净率4.74，创596天以来新低，总市值57.86亿 元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)11睿智医药-29.77-25.554.7457.86亿行业平均 40.3546.493.46158.30亿行业中值47.2152.292.7259.39亿1润达医疗-285.64189.022.47104.49亿2何氏眼 科-142.30-123.831.7733.93亿3*ST生物-118.20-114.919.7122.80亿4诚达药业-74.55-127.721.6835.89亿5普 瑞眼科-66.51-59.752.8560.87亿6皓宸医疗-52.44-63.076.2223.77亿7创新医疗-50.98-56.933.0353.48亿8国际 医学-45.16-45.423.23115.42亿9百诚医药-36.42-88.911.8446.89亿10金域医学-35.05 ...